4D Molecular Therapeutics Inc [FDMT] stock is trading at $9.97, up 3.10%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The FDMT shares have gain 19.83% over the last week, with a monthly amount glided 46.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
4D Molecular Therapeutics Inc [NASDAQ: FDMT] stock has seen the most recent analyst activity on January 13, 2025, when BMO Capital Markets downgraded its rating to a Market Perform and also revised its price target to $15 from $40. Previously, Morgan Stanley started tracking the stock with Underweight rating on November 21, 2024, and set its price target to $8. On September 23, 2024, downgrade downgraded it’s rating to Neutral. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $459 on April 15, 2024. Barclays initiated its recommendation with a Overweight and recommended $45 as its price target on April 15, 2024. In a note dated October 26, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $25 on this stock.
4D Molecular Therapeutics Inc [FDMT] stock has fluctuated between $2.23 and $10.03 over the past year. Currently, Wall Street analysts expect the stock to reach $37.11 within the next 12 months. 4D Molecular Therapeutics Inc [NASDAQ: FDMT] shares were valued at $9.97 at the most recent close of the market. An investor can expect a potential return of 272.22% based on the average FDMT price forecast.
Analyzing the FDMT fundamentals
4D Molecular Therapeutics Inc [NASDAQ:FDMT] reported sales of 0.03M for the trailing twelve months, which represents a growth of 200.00%. Gross Profit Margin for this corporation currently stands at -110.27% with Operating Profit Margin at -6676.55%, Pretax Profit Margin comes in at -5943.76%, and Net Profit Margin reading is -5943.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.4 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, 4D Molecular Therapeutics Inc’s Current Ratio is 8.75. Further, the Quick Ratio stands at 8.75, while the Cash Ratio is 2.23. Considering the valuation of this stock, the price to sales ratio is 15520.69, the price to book ratio is 1.11.
Transactions by insiders
Recent insider trading involved Bizily Scott, Chief Legal Officer, that happened on Oct 09 ’25 when 2408.0 shares were sold. Chief Legal Officer, Bizily Scott completed a deal on Sep 23 ’25 to sell 2407.0 shares. Meanwhile, Officer SCOTT BIZILY bought 7312.0 shares on Sep 23 ’25.
